🔎 Trials Near Me

Gara Jalqabaatti › Myeloma Baay’ee › Ohio › Cincinnati

Qorannoo klinikaalii Myeloma Baay’ee Cincinnati, OH keessatti

Qorannoo 17 Myeloma Baay’ee f Cincinnati fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Namoota walitti qabaa jiraSadarkaa 3
  • Research Site, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 3
  • The Christ Hospital, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07518186

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 3
  • The Christ Hospital Cancer Center, Cincinnati
  • Oncology Hematology Care, Cincinnati
  • University of Cincinnati, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05552222

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • University of Cincinnati Medical Center, Cincinnati
  • West Chester Hospital, West Chester · Miili 15 fagaatti
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT02693535

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Namoota walitti qabaa jiraSadarkaa 3
  • University of Cincinnati Medical Center, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 2
  • Oncology Hematology Care, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06297226

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 3
  • TriHealth Cancer and Blood Institute, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07555938

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Namoota walitti qabaa jiraSadarkaa 3
  • Oncology Hematology Care Clinical Trials, LLC, Cincinnati
  • TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
  • Oncology Hematology Care Clinical Trials, LLC, Cincinnati
  • fi 4 dabalataa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Namoota walitti qabaa jiraSadarkaa 3
  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • TriHealth Cancer Institute-Westside, Cincinnati
  • fi 1 dabalataa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Namoota walitti qabaa jiraSadarkaa 3
  • Research Site, Cincinnati
  • Research Site, Montgomery · Miili 11 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Hag-2026 · NCT07764978

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Namoota walitti qabaa jiraSadarkaa 1/2
  • Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ado-2026 · NCT06892522

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 1
  • University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT05650632

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Namoota walitti qabaa jiraSadarkaa 3
  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Oncology Hematology Care Inc-Kenwood, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • fi 2 dabalataa
Umuriin hundi · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT05561387

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Namoota walitti qabaa jiraSadarkaa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
Umuriin 13 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT04771572

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 2
  • Oncology Hematology Care, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Elb-2026 · NCT05972135

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Namoota walitti qabaa jiraSadarkaa 1
  • Oncology Hematology Care, Inc, Cincinnati
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2025 · NCT05722418

Qorannoo Myeloma Baay’ee magaalota biroo keessatti

Qorannoo biroo Cincinnati keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.